Trial Information

Prediction of Response to Erythropoietin Treatment in Cancer Related Anemia Patients Receiving Chemotherapy

This is an observational, prospective (study following participants forward in time),
multi-center (study conducted in more than 1 center) study to identify the predictive
factors that will effectively predict the response to erythropoietin treatment in cancer
related anemia participants receiving chemotherapy. The entire duration of study will be
approximately 1 year. Participants will primarily be evaluated for achieving at least 1 gram
per deciliter (g per dl) rise in hemoglobin (substance that carries oxygen and gives blood
its red color) level after receiving erythropoietin treatment based on National
Comprehensive Cancer Institute (NCCN) V3.2009 practice guideline criteria. Response to
erythropoietin treatment will also be predicted using other independent hematological
(related to blood) factors like C-reactive protein (CRP - is an acute serum protein released
from liver). It is associated with low hemoglobin [substance that carries oxygen and gives
blood its red color] or erythropoietin [hormone secreted by kidney that helps in formation
of red blood cells in bone marrow] resistance), erythropoietin (EPO), hemoglobin, hematocrit
(amount of red blood cells in blood), reticulocyte (immature red blood cells) count,
ferritin (a protein that stores iron and allows the body to use iron), serum iron (iron is
in the blood which is bound to transferrin) and transferring iron binding capacity (TIBC),
level. Number of blood transfusions and participants' safety will be monitored throughout
the study.